Tienda Elsevier

¿Aún no está registrado?

Información relevante

Consulte los artículos y contenidos publicados en éste medio, además de los e-sumarios de las revistas científicas en el mismo momento de publicación

Máxima actualización

Esté informado en todo momento gracias a las alertas y novedades

Promociones exclusivas

Acceda a promociones exclusivas en suscripciones, lanzamientos y cursos acreditados

Crear Mi cuenta

* = Required fields

Enter your email address

User name *

Annals of Hepatology

Buscar en

Annals of Hepatology

Toda la web

Inicio Annals of Hepatology Most often read

Annals of Hepatology

ISSN: 1665-2681

Annals of Hepatology (AoH) is an international, open access journal published bi-monthly with funds from the Fundación Clínica Médica Sur. It is the official journal of the Mexican Association of Hepatology (AMH), the Latin American Association for the Study of the Liver (ALEH), the Canadian Association for the Study of the Liver (CASL) and the Czech Society of Hepatology (CSH). AoH publishes editorials, opinions, concise reviews, original articles, brief reports, letters to the editor, news from affiliated associations, clinical practice guidelines and summaries of congresses in the field of Hepatology.

Topics covered by AoH include alcoholic liver disease, autoimmune hepatitis, biliary diseases, drug-induced liver injury, genetic liver diseases, NAFLD/NASH and viral hepatitis (HAV, HBV, HCV, HDV, HEV). Our journal seeks to publish articles on basic clinical care and translational research focused on preventing rather than treating the complications of end-stage liver disease.

See more Open Access Option

Indexed in:

Scopus, Medline, Directory of Open Access Journals (DOAJ), Science Citation Index Expanded (SCIE), SCImago Journal Rank (SJR), SNIP

See more

Follow us:

Impact factor

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years.

© Clarivate Analytics, Journal Citation Reports 2022

See more

Impact factor 2023

3.7

Citescore

CiteScore measures average citations received per document published.

See more

Citescore 2023

7.9

SJR

SRJ is a prestige metric based on the idea that not all citations are the same. SJR uses a similar algorithm as the Google page rank; it provides a quantitative and qualitative measure of the journal's impact.

See more

SJR 2023

0.289

SNIP

SNIP measures contextual citation impact by wighting citations based on the total number of citations in a subject field.

See more

SNIP 2023

0.941

View more metrics

Journal Information

Most often read

Vol. 30. Issue. 2

11605

Evolving portal hypertension through Baveno VII recommendations

Manuel Mendizabal, Guilherme Grossi Lopes Cançado, Agustín Albillos

Ann Hepatol. 2024;29:101180

11605

Full text access

Share

10939

Administration of silymarin in NAFLD/NASH: A systematic review and meta-analysis

Shudi Li, Fei Duan, Suling Li, Baoping Lu

Ann Hepatol. 2024;29:101174

10939

Full text access

Share

8840

From NAFLD to MASLD: When metabolic comorbidity matters

Shan Hong, Lei Sun, Yiwei Hao, Ping Li, Yuling Zhou, Xiuxia Liang, Julong Hu, Hongshan Wei

Ann Hepatol. 2024;29:101281

8840

Full text access

Share

8073

Alcohol-related liver disease: A global perspective

Graciela Elia Castro Narro, Luis Antonio Díaz, Eric Kauffman Ortega, María Fernanda Bautista Garín, Eira Cerda Reyes, Pindaro Sebastian Martinez Delfin, Juan Pablo Arab, Ramón Bataller

Ann Hepatol. 2024;29:101499

8073

Full text access

Share

6355

Alcohol-associated liver disease: Epidemiology and management

Helena Hernández-Évole, Natalia Jiménez-Esquivel, Elisa Pose, Ramón Bataller

Ann Hepatol. 2024;29:101162

6355

Full text access

Share

6291

Pathophysiology of ascites: The importance of the intestine. A surgical contribution to the understanding of a medical problem

Gabriel E. Gondolesi, Carolina Rumbo, Leonardo Montes, Lucia Novellis, Diego Ramisch, Ariel Riquelme Henríquez, Mariana Ortega, Federico Viano, ... Héctor Solar

Ann Hepatol. 2024;29:101498

6291

Full text access

Share

6046

A multisociety Delphi consensus statement on new fatty liver disease nomenclature

Mary E. Rinella, Jeffrey V. Lazarus, Vlad Ratziu, Sven M. Francque, Arun J. Sanyal, Fasiha Kanwal, Diana Romero, Manal F. Abdelmalek, ... NAFLD Nomenclature consensus group

Ann Hepatol. 2024;29:101133

6046

Full text access

Share

5700

Why a pinch of zinc in liver disease matters

Kurt Grüngreiff, Dirk Reinhold, Wolfgang Maret

Ann Hepatol. 2024;29:101152

5700

Full text access

Share

5651

MAFLD criteria are better than MASLD criteria at predicting the risk of chronic kidney disease

Ziyan Pan, Moutaz Derbala, Khalid AlNaamani, Hasmik Ghazinian, Jian-Gao Fan, Mohammed Eslam

Ann Hepatol. 2024;29:101512

5651

Full text access

Share

4349

Hepatic Steatosis Index (HSI): A Valuable Biomarker in Subjects with Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)

Bryan A. Priego-Parra, Arturo Triana-Romero, Génesis P. Martínez-Pérez, Sara A. Reyes-Diaz, Héctor R. Ordaz-Alvarez, Raúl Bernal-Reyes, María E. Icaza-Chávez, Sophia E. Martínez-Vázquez, ... José M. Remes-Troche

Ann Hepatol. 2024;29 Supl 2:101292.4

4349

Full text access

Share

4272

The burden of liver disease in Latin America

Luis Antonio Díaz, Marcela Villota-Rivas, Francisco Barrera, Jeffrey V. Lazarus, Marco Arrese

Ann Hepatol. 2024;29:101175

4272

Full text access

Share

4256

Optimal ALT threshold for the automated diagnosis of MASLD: A population-based study using iLFT

Jeremy Lee, Christopher J. Byrne, Paul N. Brennan, Iain MacPherson, Eleanor Dow, John F. Dillon

Ann Hepatol. 2024;29:101280

4256

Full text access

Share

4101

Matrix metalloproteinase-2 inducing COL1A1 synthesis via integrin alpha Ⅴ promotes invasion and metastasis of cholangiocarcinoma cells

Shuguang Pan, Ying Hu, Lang Gan, Jiejuan Lai, Ping Zheng, YuJun Zhang, Ling Shuai, Yan Jiang, ... Yu He

Ann Hepatol. 2024;29:101279

4101

Full text access

Share

3384

Schistosomiasis: A neglected cause of liver disease in the Philippines

Alexander M. Sy

Ann Hepatol. 2024;29:101166

3384

Full text access

Share

3383

Insulin resistance and Metabolic dysfunction-associated steatotic liver disease (MASLD): Pathways of action of hypoglycemic agents

Andrea del Carmen Maldonado-Rojas, Julia María Zuarth-Vázquez, Misael Uribe, Varenka J Barbero-Becerra

Ann Hepatol. 2024;29:101182

3383

Full text access

Share

2770

From evidence to clinical practice: Bridging the gap of new liver cancer therapies in Latin America.

Federico Piñero, Ezequiel Mauro, Paola Casciato, Alejandro Forner

Ann Hepatol. 2024;29:101185

2770

Full text access

Share

2592

A clinical review of congenital hepatic fibrosis diagnosed in adulthood: presentation, complications, and outcomes

Lauren Loeb, Jason Lewis, Zhongwei Peng, Michael G. Heckman, Raouf Nakhleh, Andrew P. Keaveny

Ann Hepatol. 2024;29:101164

2592

Full text access

Share

2574

Palliative care and end stage liver disease: A cohort analysis of palliative care use and factors associated with referral

Hugo M Oliveira, Helena Pessegueiro Miranda, Francisca Rego, Rui Nunes

Ann Hepatol. 2024;29:101518

2574

Full text access

Share

2535

Liquid biopsy: New opportunities for precision medicine in hepatocellular carcinoma care

Inah Marie C. Aquino, Devis Pascut

Ann Hepatol. 2024;29:101176

2535

Full text access

Share

2426

Prevalence of occult hepatitis B virus infection and characterisation of hepatitis B surface antigen mutants among adults in western Croatia

Marina Bubonja-Šonje, Dolores Peruč, Maja Abram, Bojana Mohar-Vitezić

Ann Hepatol. 2024;29:101156

2426

Full text access

Share